TMO · Thermo Fisher Scientific Inc.

Thermo Fisher Scientific reported strong first quarter 2026 results, with revenue of $11.01 billion, up 6% year-over-year, driven by 1% organic growth, 3% from acquisitions, and 2% from currency translation. GAAP diluted EPS grew 11% to $4.43, while adjusted EPS rose 6% to $5.44. The company's GAAP operating margin expanded 30 basis points to 16.9%, while adjusted operating margin slightly contracted to 21.8% from 21.9% in the prior year. Segment performance was led by Life Sciences Solutions, which grew 12.6% to $2.64 billion, reflecting strong demand. The company completed the acquisition of Clario, an endpoint data solutions provider, and announced strategic collaborations with NVIDIA and SHL Medical to advance scientific instrumentation and drug product manufacturing. Management highlighted the strength of the PPI Business System and the successful execution of capital deployment, including $3.0 billion in share repurchases and a 10% dividend increase. No specific forward guidance was provided in the press release, but the company indicated it would update 2026 financial guidance during the earnings call. The results demonstrate Thermo Fisher's ability to deliver consistent growth and operational excellence, positioning it well for the remainder of the year.